Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.47 |
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DRD1 | P21728 | 4/20 | 0.44 |
| ▸ | DRD5 | P21918 | 4/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394587 | 0.99 | RORC (0.50) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL1394583 | 0.87 | RORC (0.50) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL2743840 | 0.83 | CHRM2 (0.54) | RORCHRH3DRD2DRD4DRD3 | |
| SCHEMBL8606442 | 0.82 | HDAC1 (0.53) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL6719487 | 0.81 | HDAC1 (0.53) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL10490519 | 0.80 | HRH3 (0.52) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL10092656 | 0.79 | MEN1 (0.57) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL917255 | 0.78 | DRD2 (0.57) | DRD2DRD4DRD3 | |
| SCHEMBL28805650 | 0.78 | HDAC1 (0.53) | RORCHDAC1HDAC6CREBBPBRD4 | |
| SCHEMBL2743717 | 0.78 | CHRM2 (0.47) | RORCHRH3DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010404-A1 | OXAZINE DYES WITH IMPROVED AQUEOUS SOLUBILITY | SIGMA-ALDRICH CO. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2300445-A1 | OXAZINE DYES WITH IMPROVED AQUEOUS SOLUBILITY | Sigma-Aldrich Co. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009152024-A1 | OXAZINE DYES WITH IMPROVED AQUEOUS SOLUBILITY | SIGMA-ALDRICH CO. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010404-A1 | OXAZINE DYES WITH IMPROVED AQUEOUS SOLUBILITY | OXA1L, PPOX, CRYZ | RORC 214/4885HDAC1 1870/4885HDAC6 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.